Kerrie Brady

Kerrie Brady is currently an advisor at Invea Therapeutics. Kerrie has extensive experience in the biotech industry, having co-founded and served as Chief Business Officer at Centrexion Therapeutics Corp. and Chief Operations Officer at Vallinex Inc.

At Centrexion, Kerrie helped grow the company from 2 to 25 team members, with 5 clinical programs in progress. Under their guidance, the company adopted new technology solutions such as AI, translation models, and innovative clinical trial strategies to optimize product development. They were also able to secure $150M in investments via 3 rounds of VC and private investor funding. One of their biggest accomplishments was negotiating a $998M licensing deal ($48M up-front) with Eli Lilly for a Phase 1 asset - the largest ever agreement for a pain drug. Additionally, Kerrie spearheaded the acquisition of 3 early-stage assets from Boehringer Ingelheim and successfully transitioned them into clinical development before launching them onto commercial markets.

Outside of their work at Centrexion, Kerrie participated in an opioid working group with the Biotechnology Innovation Organization (BIO). Here, they played a key role in lobbying, legislation, and program activities related to the opioid crisis.

Kerrie Brady has a Master of Science in Biopharmaceuticals from the University of New South Wales, an MBA in Management from Melbourne Business School, and a Bachelor of Pharmacy from Monash University.